Zobrazeno 1 - 10
of 19 039
pro vyhledávání: '"CAR T"'
Autor:
Yifan Zhao, Xue Bai, Shujing Guo, Xiaomei Zhang, Jile Liu, Mohan Zhao, Tianle Xie, Haotian Meng, Yu Zhang, Xiaoyuan He, Mingfeng Zhao
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-12 (2024)
Abstract Backgrounds The incidence of extramedullary diseases (EMDs) in patients diagnosed with acute myeloid leukemia (AML) is approximately 10–20%. These patients exhibit a significantly distinct etiology, therapeutic response, and prognosis comp
Externí odkaz:
https://doaj.org/article/9d8c908327c64487b539ed227c0ce396
Autor:
Xianjun Li, Tianjun Chen, Xuehan Li, Hanyu Zhang, Yingjing Li, Shuyuan Zhang, Shengnan Luo, Tongsen Zheng
Publikováno v:
Experimental Hematology & Oncology, Vol 13, Iss 1, Pp 1-20 (2024)
Abstract Chimeric antigen receptor (CAR) T cell therapy, which targets tumors with high specificity through the recognition of particular antigens, has emerged as one of the most rapidly advancing modalities in immunotherapy, demonstrating substantia
Externí odkaz:
https://doaj.org/article/856a1647235f462793d6ed0e80614606
Publikováno v:
Onco, Vol 4, Iss 3, Pp 232-240 (2024)
The use of chimeric antigen receptors (CAR T-cells) for the treatment of patients with malignant haematological diseases has become a well-established application for conditions such as refractory or relapsed B-cell acute lymphoblastic leukaemia (B-A
Externí odkaz:
https://doaj.org/article/681b84c48d244b28a1b50f50a66d3c15
Autor:
Angela C. Court, Eliseo Parra-Crisóstomo, Pablo Castro-Córdova, Luiza Abdo, Emmanuel Arthur Albuquerque Aragão, Rocío Lorca, Fernando E. Figueroa, Martín Hernán Bonamino, Maroun Khoury
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-15 (2024)
Abstract Background Apoptosis, a form of programmed cell death, is critical for the development and homeostasis of the immune system. Chimeric antigen receptor T (CAR-T) cell therapy, approved for hematologic cancers, retains several limitations and
Externí odkaz:
https://doaj.org/article/d0d64939ef1b4ab188402484e84e7de2
Autor:
François Volery, Yara Banz, Alexander Heini, Marie-Noelle Kronig, Daniel Siegrist, Michael Daskalakis, Ulrike Bacher, Thomas Pabst
Publikováno v:
Case Reports in Oncology, Vol 17, Iss 1, Pp 1087-1093 (2024)
Introduction: The introduction of CAR-T cell treatment for relapsed/refractory (r/r) mantle cell lymphoma improved survival rates of these patients. Along with its introduction in clinical routine, long-term events after CAR-T cell treatment are incr
Externí odkaz:
https://doaj.org/article/3f2333b5f2a14159b247389e3703aeb4
Autor:
Fatemeh Nasiri, Yasaman Asaadi, Farzaneh Mirzadeh, Shahrokh Abdolahi, Sedigheh Molaei, Somayeh Piri Gavgani, Fatemeh Rahbarizadeh
Publikováno v:
Biomarker Research, Vol 12, Iss 1, Pp 1-31 (2024)
Abstract Multiple myeloma (MM) is a hematological cancer characterized by the abnormal proliferation of plasma cells. Initial treatments often include immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and monoclonal antibodies (mAbs). Desp
Externí odkaz:
https://doaj.org/article/6b0a7e5a21414a61a1cddb7dba91e414
Autor:
Ling-Shuang Sheng, Rong Shen, Zi-Xun Yan, Chao Wang, Xin Zheng, Yi-Lun Zhang, Hao-Xu Yang, Wen Wu, Peng-Peng Xu, Shu Cheng, Emmanuel Bachy, Pierre Sesques, Nicolas Jacquet-Francillon, Xu-Feng Jiang, Wei-Li Zhao, Li Wang
Publikováno v:
Biomarker Research, Vol 12, Iss 1, Pp 1-7 (2024)
Abstract Chimeric antigen receptor T (CAR-T) cell therapy has greatly improved the prognosis of relapsed and refractory patients with large B-cell lymphoma (LBCL). Early identification and intervention of patients who may respond poorly to CAR-T cell
Externí odkaz:
https://doaj.org/article/4b9725d563dd402392bbdf87337f7ad2
Autor:
Adrien Krug, Aymen Saidane, Chiara Martinello, Floriane Fusil, Alexander Michels, Christian J. Buchholz, Jean-Ehrland Ricci, Els Verhoeyen
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 43, Iss 1, Pp 1-18 (2024)
Abstract Background For angioimmunoblastic T cell lymphoma (AITL), a rare cancer, no specific treatments are available and survival outcome is poor. We previously developed a murine model for AITL that mimics closely human disease and allows to evalu
Externí odkaz:
https://doaj.org/article/daf8777c96c74d378e623fabf71e0eca
Autor:
Shafieeh Mansoori, Ahmad Noei, Amirhosein Maali, Seyedeh Sheila Seyed-Motahari, Zahra Sharifzadeh
Publikováno v:
Cancer Cell International, Vol 24, Iss 1, Pp 1-22 (2024)
Abstract CAR-T cell therapy is known as an effective therapy in patients with hematological malignancies. Since 2017, several autologous CAR-T cell (auto-CAR-T) drugs have been approved by the US Food and Drug Administration (FDA) for the treatment o
Externí odkaz:
https://doaj.org/article/8699bf73261d447d9122bc152fd6efde
Autor:
Shigui Zhu
Publikováno v:
Journal of the National Cancer Center, Vol 4, Iss 3, Pp 189-194 (2024)
Chimeric antigen receptor (CAR) T-cell therapy has emerged as a groundbreaking approach in cancer treatment, utilizing the immune system's capabilities to combat malignancies. This innovative therapy involves extracting T-cells from a patient's blood
Externí odkaz:
https://doaj.org/article/1529e7155cad46549267e79b56ee9173